Şebnem YALÇINKAYA

Professor Dr Şebnem Erçalık Yalçınkaya was born in 1971 in Istanbul. She  graduated from Marmara University, Faculty of Dentistry in 1993 and took her PhD in 2000 in the Department of oral Diagnosis and Radiology. Between 2003-2005, she worked as a guest researcher in Düsseldorf-Germany, Heinrich Heine University and she took part in research projects on exfoliative cytology and DNA-cytometry for early diagnosis or oral cancer at the Cytopathology Institute and on the digital dental radiology at Faculty of Dentistry. Dr Yalçınkaya became an associate professor in 2008 and full professor in 2015 at Marmara University. She is currently the head of the Department of Oral and Maxillofacial Radiology at Marmara University. She has memberships in professional organizations; Turkish Association of Oral Diagnosis and Maxillofacial Radiology, International Association of Maxillofacial Radiology and European Academy of Maxillofacial Radiology. She is married with two children.

 

Potantially Malignant Oral Lesions and Non-invasive Diagnostic Methods


Almost half of the oral cancer cases are already in late stages (Stages III, IV) when they are diagnosed. It is known that they could have been aforetime diagnosed with conventional intra-oral examination. It has been reported that the incidence rate of some cancers is decreasing overall, however, the incidence rate of cancers of the tongue, oropharynx and tonsil is still increasing. Early diagnosis of oral cancer is crucial to improve the patient’s survival rate. However, because of the poor diagnosis of the pre-malignant and malignant lesions, morbidity and mortality have not decreased over the past 50 years. Early-stage lesions may be asymptomatic and resemble benign lesions whereas some alterations may not be readily evident in routine conventional white light oral examination. In order to detect oral pre-malignancy and malignancy, new technologies with new diagnostic tools for localizing or emphasizing dysplasia and biological characteristics of mucosal lesions have been proposed. Potential oral premalignant lesions and adjunctive screening technologies which are on the market will be evaluated in this presentation.